Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Several Phase-II trials have been designed to evaluate Tyrosine Kinase Inhibitor (TKI) and in particular Pazopanib in Neuroendocrine Neoplasia (NEN) but it’s efficacy is not yet demonstrated in a randomized Phase III trial.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Bongiovanni A, Liverani C, Recine f, Fausti V, Mercatali L,
Keywords: pazopanib, neuroendocrine neoplasia, neuroendocrine tumors, meta-analysis, carcinoid,
Introduction: Poorly differentiated, G3 NECs are associated with poor outcomes and have no effective treatment options apart from cytotoxic chemotherapy.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Rodriguez-Freixinos V
Authors: Rodriguez-Freixinos V, Chan D, Doherty M, Wasson K, Iscoe N,
Keywords: Poorly differentiated, G3 NECs, Avelumab, Immunotherapy,
Introduction: Chemotherapy is often combined with PRTT to treat NETs of pancreatic or midgut origin (pNET/mNET) based on the principle of radiosensitization.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Pavlakis N
Authors: Pavlakis N, Ransom D, Wyld D, Sjoquist K, Asher R,
Keywords: Lutate, PRRT, chemotherapy, CAPTEM, NETs,
Introduction: Progression-free survival (PFS) has been used as surrogate endpoint in phase III trials with somatostatin analogues for gastroentero-pancreatic neuroendocrine tumors (GEP-NET). However, this endpoint has not been validated in this scenario.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Jimenez Fonseca P
Authors: Jimenez-Fonseca P, Carmona-Bayonas A, Lamarca A, Barriuso J, Castaño A,
Keywords: somatostatin analogues, surrogate, PFS, OS, correlation, kendall,
Introduction: Metastatic WHO grade 3 extra-pulmonary neuroendocrine carcinomas (EP-NEC) have a poor prognosis and optimal treatment after first-line platinum-etoposide chemotherapy remains unclear. A recent, small phase II study combining ipilimumab and nivolumab showed promising results
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Vandamme T, De Backer L, Van den Brande J, Op de Beeck B, Driessen A,
Keywords: NEC, immunotherapy,